Lead Evaluation for Defibrillation and Reliability Post Approval Study
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Medtronic
- Study ID
- NCT07005232
- Status
- Enrolling By Invitation
Conditions
- Tachyarrhythmia
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- defibrillation lead — DEVICEThis is a device registry for the OmniaSecure™ defibrillation lead. The OmniaSecure lead is a steroid eluting, integrated bipolar, nonretractable screw-in, catheter delivered, transvenous ventricular lead with a Right Ventricular (RV) defibrillation coil electrode. The lead is designed for pacing, sensing, cardioversion, and defibrillation therapies, and has application for patients whom transvenous ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated.
Study Details
Medtronic is sponsoring the LEADR PAS to provide continuing evaluation and periodic reporting of safety and effectiveness of the OmniaSecure™ defibrillation lead following commercial release. The LEADR PAS is conducted within Medtronic's Product Surveillance Registry Platform (NCT01524276).
Key Dates
- Start date
- Jan 7, 2026
- Status verified
- May 2025
- Primary completion
- Sep 30, 2032
- Completion
- Sep 30, 2032
Study Design
- Enrollment
- 2,000 participants (estimated)
Primary Outcome Measure
Complication Survival Rate [ Time Frame: 5 years ]
Locations (46)
Find similar trials in Birmingham, AL
Related Studies
- Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGsRecruiting · Virginia Commonwealth University · Richmond, Virginia